国药股份(600511.SH)：2025年中报净利润为9.49亿元、同比较去年同期下降5.19%

Financial Performance - The company reported total revenue of 25.634 billion, an increase of 877 million compared to the same period last year, marking a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders was 949 million, a decrease of 51.963 million from the same period last year, reflecting a year-on-year decline of 5.19% [1] - The net cash inflow from operating activities was -1.510 billion, a decrease of 444 million compared to the same period last year [1] Key Financial Ratios - The latest debt-to-asset ratio is 44.41%, a decrease of 0.14 percentage points from the previous quarter and a decrease of 2.12 percentage points from the same period last year [3] - The latest gross profit margin is 6.14%, down 0.18 percentage points from the previous quarter and down 0.94 percentage points from the same period last year [3] - The latest return on equity (ROE) is 5.43%, a decrease of 0.78 percentage points from the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 1.26, a decrease of 0.07 from the same period last year, reflecting a year-on-year decline of 5.20% [3] - The latest total asset turnover ratio is 0.74 times, a decrease of 0.01 times from the same period last year [3] - The latest inventory turnover ratio is 4.69 times, a decrease of 0.47 times from the same period last year, reflecting a year-on-year decline of 9.04% [3] Shareholder Information - The number of shareholders is 47,400, with the top ten shareholders holding a total of 522 million shares, accounting for 69.25% of the total share capital [3] - The largest shareholder is China National Pharmaceutical Group Co., Ltd., holding 54.7% of the shares [3]